Benitec Biopharma Inc. Quarterly Debt-to-equity in % from Q1 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Benitec Biopharma Inc. quarterly Debt-to-equity history and growth rate from Q1 2021 to Q3 2024.
  • Benitec Biopharma Inc. Debt-to-equity for the quarter ending September 30, 2024 was 13.7 %, a 67.9% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 13.7 -28.9 -67.9% Sep 30, 2024
Q2 2024 19.8 -30 -60.2% Jun 30, 2024
Q1 2024 37.2 -4.53 -10.9% Mar 31, 2024
Q4 2023 43.1 +7.67 +21.7% Dec 31, 2023
Q3 2023 42.6 +8.24 +24% Sep 30, 2023
Q2 2023 49.7 +19.3 +63.4% Jun 30, 2023
Q1 2023 41.7 +24.1 +138% Mar 31, 2023
Q4 2022 35.4 +19 +116% Dec 31, 2022
Q3 2022 34.4 +22.7 +195% Sep 30, 2022
Q2 2022 30.4 +19.3 +173% Jun 30, 2022
Q1 2022 17.6 +3.97 +29.2% Mar 31, 2022
Q4 2021 16.4 Dec 31, 2021
Q3 2021 11.7 Sep 30, 2021
Q2 2021 11.1 Jun 30, 2021
Q1 2021 13.6 Mar 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.